INTRODUCTION: Inhaled corticosteroids (ICS) are a first-line treatment for mild persistent asthma, but montelukast (MON) monotherapy also has been beneficial. The aim of this review is to evaluate current evidence comparing MON versus ICS monotherapy in pediatric patients. METHOD: A systematic review was conducted of randomized controlled trials evaluating treatment of mild to moderate persistent asthma in which MON was compared with ICS monotherapy in children aged 2 to 18 years. PubMed, the Cumulative Index to Nursing and Allied Health Literature, and the Institute of Scientific Information's Web of Knowledge were searched using key words asthma, MON, and ICS. Studies that met inclusion criteria were appraised for quality. RESULTS: Of 214 identified studies, eight met inclusion criteria and seven were deemed high quality. Study sample sizes ranged from 62 to 994, 88% were multi-site, and the average length of follow-up was 8.2 months. Asthma symptoms improved with both therapies. Four studies reported superiority of ICS compared with MON; the remaining studies showed no differences between therapies. DISCUSSION: These results are consistent with the National Asthma Education and Prevention Program (2007) recommendation that ICS therapy should be first-line treatment in children with mild to moderate persistent asthma.
INTRODUCTION: Inhaled corticosteroids (ICS) are a first-line treatment for mild persistent asthma, but montelukast (MON) monotherapy also has been beneficial. The aim of this review is to evaluate current evidence comparing MON versus ICS monotherapy in pediatric patients. METHOD: A systematic review was conducted of randomized controlled trials evaluating treatment of mild to moderate persistent asthma in which MON was compared with ICS monotherapy in children aged 2 to 18 years. PubMed, the Cumulative Index to Nursing and Allied Health Literature, and the Institute of Scientific Information's Web of Knowledge were searched using key words asthma, MON, and ICS. Studies that met inclusion criteria were appraised for quality. RESULTS: Of 214 identified studies, eight met inclusion criteria and seven were deemed high quality. Study sample sizes ranged from 62 to 994, 88% were multi-site, and the average length of follow-up was 8.2 months. Asthma symptoms improved with both therapies. Four studies reported superiority of ICS compared with MON; the remaining studies showed no differences between therapies. DISCUSSION: These results are consistent with the National Asthma Education and Prevention Program (2007) recommendation that ICS therapy should be first-line treatment in children with mild to moderate persistent asthma.
Authors: Cynthia J Koziol-White; Yanlin Jia; Gretchen A Baltus; Philip R Cooper; Dennis M Zaller; Michael A Crackower; Erich E Sirkowski; Steven Smock; Alan B Northrup; Blanca E Himes; Stephen E Alves; Reynold A Panettieri Journal: Br J Pharmacol Date: 2016-10-05 Impact factor: 8.739